Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

DI Bernstein, FM Munoz, ST Callahan, R Rupp… - Vaccine, 2016 - Elsevier
Background Cytomegalovirus (CMV) is a leading cause of congenital infection and an
important target for vaccine development. Methods CMV seronegative girls between 12 and …
被引用次数：223 相关文章

[引用][C] Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

DI Bernstein, FM Munoz, ST Callahan, R Rupp… - Vaccine, 2016 - cir.nii.ac.jp
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A
randomized clinical trial | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.

DI Bernstein, FM Munoz, ST Callahan, R Rupp… - Vaccine, 2015 - europepmc.org
Background Cytomegalovirus (CMV) is a leading cause of congenital infection and an
important target for vaccine development. Methods CMV seronegative girls between 12 and …

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

DI Bernstein, FM Munoz, ST Callahan, R Rupp… - Vaccine, 2016 - infona.pl
Cytomegalovirus (CMV) is a leading cause of congenital infection and an important target for
vaccine development. CMV seronegative girls between 12 and 17 years of age received …
[PDF] academia.edu

[PDF][PDF] Safety and Efficacy of a Cytomegalovirus Glycoprotein B (gB) Vaccine in Adolescent Girls: a Randomized Clinical Trial

DI Bernstein, FM Munoz, ST Callahan, R Rupp… - Vaccine, 2016 - academia.edu
Background—Cytomegalovirus (CMV) is a leading cause of congenital infection and an
important target for vaccine development. Methods—CMV seronegative girls between 12 …

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

DI Bernstein, FM Munoz, ST Callahan, R Rupp… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Cytomegalovirus (CMV) is a leading cause of congenital infection and an
important target for vaccine development. Methods CMV seronegative girls between 12 and …

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial.

DI Bernstein, FM Munoz, ST Callahan, R Rupp… - 2016 - cabidigitallibrary.org
Background: Cytomegalovirus (CMV) is a leading cause of congenital infection and an
important target for vaccine development. Methods: CMV seronegative girls between 12 and …

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

DI Bernstein, FM Munoz, ST Callahan, R Rupp… - …, 2016 - researchexperts.utmb.edu
Background: Cytomegalovirus (CMV) is a leading cause of congenital infection and an
important target for vaccine development. Methods: CMV seronegative girls between 12 and …
[HTML] nih.gov

[HTML][HTML] Safety and Efficacy of a Cytomegalovirus Glycoprotein B (gB) Vaccine in Adolescent Girls: a Randomized Clinical Trial

DI Bernstein, FM Munoz, ST Callahan, R Rupp… - Vaccine, 2016 - ncbi.nlm.nih.gov
Background Cytomegalovirus (CMV) is a leading cause of congenital infection and an
important target for vaccine development. Methods CMV seronegative girls between 12 and …

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.

DI Bernstein, FM Munoz, ST Callahan, R Rupp… - Vaccine, 2015 - europepmc.org
Background Cytomegalovirus (CMV) is a leading cause of congenital infection and an
important target for vaccine development. Methods CMV seronegative girls between 12 and …